Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
Phase 2
Completed
- Conditions
- Moderate to Severe GoutHyperuricemia
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01109121
- Locations
- ๐บ๐ธ
Nuon Investigative Site, Spokane, Washington, United States
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
Phase 2
Completed
- Conditions
- GoutHyperuricemia
- Interventions
- Drug: TranilastDrug: AllopurinolDrug: Combination - Tranilast and AllopurinolDrug: 400 mg AllopurinolDrug: High dose combination
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01052987
- Locations
- ๐บ๐ธ
Nuon Investigative Site, Dallas, Texas, United States
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
Phase 2
Completed
- Conditions
- GoutHyperuricemia
- Interventions
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00995618
- Locations
- ๐บ๐ธ
Nuon Investigative Site, Dallas, Texas, United States
Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2011-01-06
- Lead Sponsor
- Nuon Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT00882024
ยฉ Copyright 2025. All Rights Reserved by MedPath